These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23537151)

  • 1. Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges.
    Gemal A; Keravec J; Menezes A; Trajman A
    BMC Public Health; 2013 Mar; 13():279. PubMed ID: 23537151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility.
    Lunte K; Cordier-Lassalle T; Keravec J
    Bull World Health Organ; 2015 Apr; 93(4):279-82. PubMed ID: 26229192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs.
    Laing RO; McGoldrick KM
    Int J Tuberc Lung Dis; 2000 Dec; 4(12 Suppl 2):S194-207. PubMed ID: 11144553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Global Drug Facility and its role in the market for tuberculosis drugs.
    Arinaminpathy N; Cordier-Lassalle T; Vijay A; Dye C
    Lancet; 2013 Oct; 382(9901):1373-9. PubMed ID: 23726162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health. Responding to market failures in tuberculosis control.
    Gupta R; Kim JY; Espinal MA; Caudron JM; Pecoul B; Farmer PE; Raviglione MC
    Science; 2001 Aug; 293(5532):1049-51. PubMed ID: 11463877
    [No Abstract]   [Full Text] [Related]  

  • 6. Pediatric tuberculosis drug market: an insider perspective on challenges and solutions.
    Usherenko I; Basu Roy U; Mazlish S; Liu S; Benkoscki L; Coutts D; Epstein S; Qian M; Rafiq S; Scott C
    Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():23-31. PubMed ID: 26564537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New tuberculosis drugs in resistant and multiresistant tuberculosis].
    Ramírez Lapausa M; Pascual Pareja JF; Noguerado Asensio A
    Med Clin (Barc); 2013 Oct; 141(7):306-13. PubMed ID: 23540388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tuberculosis in Asia].
    Kekkaku; 2002 Oct; 77(10):693-7. PubMed ID: 12440145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirements for anti-tuberculosis drug tender requests.
    Trébucq A; Caudron JM; Pinel J
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S358-61; discussion S381-7. PubMed ID: 10593718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer.
    Anyakora C; Ekwunife O; Alozie F; Esuga M; Ukwuru J; Onya S; Nwokike J
    BMC Health Serv Res; 2017 Sep; 17(1):665. PubMed ID: 28923044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimate of the global market for rifampicin-containing fixed-dose combination tablets.
    Norval PY; Blomberg B; Kitler ME; Dye C; Spinaci S
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S292-300; discussion S317-21. PubMed ID: 10593708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis: a new vision for the 21st century.
    Small PM
    Kekkaku; 2009 Nov; 84(11):721-6. PubMed ID: 19999594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-drug resistant tuberculosis burden and risk factors: an update.
    Marahatta SB
    Kathmandu Univ Med J (KUMJ); 2010; 8(29):116-25. PubMed ID: 21209520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacopoeia as quality codex for the manufacturers.
    Soldi A
    Ann Ist Super Sanita; 1975; 11(3-4):269-80. PubMed ID: 1234728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective.
    Scott C; Gardiner E; de Lucia A
    Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():17-22. PubMed ID: 26564536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Global TB Drug Facility: innovative global procurement.
    Kumaresan J; Smith I; Arnold V; Evans P
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):130-8. PubMed ID: 14974756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities.
    Chaulet P
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S353-7; discussion S381-7. PubMed ID: 10593717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Size and usage patterns of private TB drug markets in the high burden countries.
    Wells WA; Ge CF; Patel N; Oh T; Gardiner E; Kimerling ME
    PLoS One; 2011 May; 6(5):e18964. PubMed ID: 21573227
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.